Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A

Journal article

Open access

Peer reviewed

Praveen Vikas, Larissa A. Korde, Mark R. Somerfield and Dawn L. Hershman

JCO oncology practice, Vol.18(9), pp.649-651

09/01/2022

DOI: 10.1200/OP.22.00284

PMID: 35728019

Files and links (1)

url

https://doi.org/10.1200/OP.22.00284View

Published (Version of record) Open Access

no abstract

Oncology

Life Sciences & Biomedicine

Science & Technology

Title: Subtitle: Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
Creators: Praveen Vikas - University of Iowa
Larissa A. Korde - Clinical Investigations Branch, CTEP, DCTD, National Cancer Institute, Bethesda, MD.
Mark R. Somerfield - American Society of Clinical Oncology
Dawn L. Hershman - Columbia University
Resource Type: Journal article
Publication Details: JCO oncology practice, Vol.18(9), pp.649-651
DOI: 10.1200/OP.22.00284
PMID: 35728019
NLM abbreviation: JCO Oncol Pract
ISSN: 2688-1527
eISSN: 2688-1535
Publisher: Lippincott Williams & Wilkins
Number of pages: 4
Language: English
Date published: 09/01/2022
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984359568602771

19 Record Views